BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 38688713)

  • 1. A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors.
    Yeung SJ; Qdaisat A; Bischof JJ; Caterino JM; Kyriacou DN; Coyne Md C
    Am J Emerg Med; 2024 Jun; 80():227.e1-227.e5. PubMed ID: 38705758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department.
    Castillo RM; Sandefur BJ; Finch AS; Richter MD; Thanarajasingam U
    Mayo Clin Proc Innov Qual Outcomes; 2021 Dec; 5(6):1029-1035. PubMed ID: 34765885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
    Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
    Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department.
    Pini F; Grigoriu B; Lieveke A; Meert AP
    Emerg Med J; 2024 Apr; ():. PubMed ID: 38688713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
    Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
    ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
    Fahey CC; Gracie TJ; Johnson DB
    Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
    Das S; Johnson DB
    J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.